Collplant announces $3.7 million private placement

Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 // -- CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered warrants to purchase up to 1,483,952 ordinary shares in a private placement at a combined purchase price of $3.74 per ordinary share and accompanying warrants (or $3.7399 per ordinary share equivalent and accompanying warrants). The private placement, which is comprised primarily of the Company's existing investors, reflects confidence in CollPlant's expanded strategic vision and its execution capabilities in deep-tech photonic computing. The warrants will have an exercise price of $3.74 per share, will be exercisable immediately upon issuance and will expire five years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The private placement is expected to close on or about October 14, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. and Rodman & Renshaw LLC are acting as the exclusive joint placement agents for the private placement. The gross proceeds from the private placement, before deducting the placement agent's fees and other related expenses payable by the Company, are expected to be approximately $3.7 million. CollPlant intends to use the net proceeds from this offering primarily to accelerate the research and development programs of its subsidiary, LightSolver, focusing on the advancement and scalability of its proprietary laser-based supercomputing architecture and Laser Processing Unit (LPU(TM)) technology as well as general corporate purposes including working capital. The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of the securities purchase agreement entered into with the investors, the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the ordinary shares and ordinary shares underlying the warran